What is the recommended emergency department treatment for acute migraine?

Emergency Department Treatment of Acute Migraine

For adults presenting to the ED with acute migraine requiring parenteral therapy, prochlorperazine IV (10 mg) or greater occipital nerve blocks (GONB) must be offered as first-line treatment 1.

First-Line Parenteral Therapies (Level A - Must Offer)

The 2025 AHS guideline provides the strongest evidence for:

• Prochlorperazine IV: Multiple class I studies demonstrate highly likely efficacy for acute migraine treatment in the ED setting 1
• Greater Occipital Nerve Blocks (GONB): Also supported by multiple class I studies showing highly likely effectiveness 1

These represent the only "must offer" recommendations based on the most recent and highest quality evidence.

Second-Line Options (Level B - Should Offer)

When first-line therapies are contraindicated or unavailable, the following should be offered 1:

• Dexketoprofen IV or Ketorolac IV: NSAIDs with proven efficacy (highly likely and likely effective, respectively)
• Metoclopramide IV: Likely effective based on class I evidence, though slightly lower strength recommendation than prochlorperazine
• Sumatriptan SC: Highly likely effective for migraine-specific treatment
• Supraorbital Nerve Blocks (SONB): Likely effective based on class I evidence

The 2024 VA/DoD guideline also gives strong support to aspirin-acetaminophen-caffeine combinations for outpatient settings, though this is less relevant for ED parenteral therapy 2.

Additional Considerations (Level C - May Offer)

• Chlorpromazine IV: May be offered but has higher risk of akathisia and sedation 1
• Dexamethasone IV: Should be offered specifically to prevent headache recurrence after ED discharge (Level B from 2016 guideline, maintained in 2025) 3, 1
• Valproate IV: May be offered as an alternative 1

Critical Pitfall: What NOT to Use

Hydromorphone IV must NOT be offered (Level A - must not offer) 1. This represents a significant shift from historical practice:

• Class I studies demonstrate hydromorphone is likely ineffective for migraine pain
• Opioids generally lack efficacy and carry risks of dependence and medication overuse headache
• The 2016 guideline recommended avoiding morphine and hydromorphone as first-line therapy 3; the 2025 update strengthens this to "must not offer" 1

Paracetamol (acetaminophen) IV should not be offered (Level C) based on likely ineffective evidence 1.

Practical Treatment Algorithm

Step 1: Assess for contraindications to dopamine antagonists (extrapyramidal symptoms, QT prolongation) or nerve blocks (local infection, coagulopathy)

Step 2: Administer prochlorperazine 10 mg IV OR perform GONB if trained

• Consider adding diphenhydramine 25-50 mg IV to reduce akathisia risk with prochlorperazine

Step 3: If inadequate response after 30-60 minutes, consider:

• Ketorolac 30 mg IV or dexketoprofen IV
• Metoclopramide 10 mg IV (if not already given)
• Sumatriptan 6 mg SC (if no vascular contraindications)

Step 4: At discharge, administer dexamethasone 10-24 mg IV to prevent 24-72 hour headache recurrence 3, 1

Managing Nausea

Treat nausea aggressively as it is one of the most disabling migraine symptoms 4. The dopamine antagonists (prochlorperazine, metoclopramide) serve dual purposes as both antimigraine and antiemetic agents. Consider non-oral routes early if nausea/vomiting is prominent 4.

Common Pitfalls to Avoid

1. Defaulting to opioids: Despite historical use, evidence clearly shows opioids are ineffective and potentially harmful 1
2. Underdosing antiemetics: Antiemetics should not be restricted only to vomiting patients—nausea itself requires treatment 4
3. Forgetting discharge prophylaxis: Headache recurrence exceeds 50% without dexamethasone 5
4. Using propofol or ketamine: Current evidence shows no clear role for these agents in ED migraine treatment 6, 1

Special Populations

For patients with contraindications to dopamine antagonists (Parkinson's disease, neuroleptic sensitivity), nerve blocks or NSAIDs become primary options. For those with cardiovascular risk factors, avoid triptans and consider dopamine antagonists or NSAIDs instead 2.